Active Pharmaceutical Ingredient (API) Market by type (Innovative, generic), manufacturer (captive, merchant), synthesis (synthetic, biotech), by product (vaccines, Hormones), drug (OTC, Rx), application (Diabetes, oncology, CVD)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2021-2027

The global Active Pharmaceutical Ingredient (API) market gathered revenue around USD 187.9 Billion in 2020 and market is set to grow USD 249.7 Billion by the end of 2027 and is estimated to expand at a modest CAGR of 6.1% during the prediction period 2021 to 2027.

Growth Factors:

The market is driven by the growth of the biopharmaceutical sector, advancements in active pharmaceutical ingredient (API) manufacturing, and an increase in the geriatric population.

The growth of the captive API segment is propelled by companies investing in solving challenges and developing new chemical ways for the production of APIs in house. This aids in reducing costs and the risk of contamination. Artificial intelligence and protein synthesis are expected to facilitate faster development with greater control over the process.

The rising prevalence of chronic and lifestyle-based conditions, such as cardiovascular diseases, is accelerating the demand for API. For instance, as per U.S. Pharmacist in 2020, 47% of adults have at least one risk factor that supports cardiovascular disease development. Cardiovascular diseases are one of the global, critical public health burdens driving extensive R&D for APIs in the field.

The generic API segment is gaining share in the market owing to its cost effectiveness, which helps in catering to the needs of the rising number of patients in developing regions with a low-income population. According to the Association for Accessible Medicines (AAM), in 2017, there was a considerable rise in manufacturing units in Asia, Australia, and EU5. There has also been an increase in the market share of generic drugs.

Developing nations like India are receiving an increased preference in the market over dominant API market countries, like China, owing to geopolitical situations. Furthermore, other factors favoring India include quality raw materials and products, large workforce, vast distribution network, and government subsidies under schemes like "Make in India".

For addressing unmet medical needs, companies are collaborating to develop novel treatments. This allows firms to use their resources to aid in the development of products and enhance the supply chain. In August 2019, OmniChem Private Limited was acquired by Ajinomoto Bio-Pharma Services (earlier they were in a joint venture since 2011 for the manufacturing of APIs). The acquisition was completed in June 2020.

This research report purposes at stressing the most lucrative growth prospects. The aim of the research report is to provide an inclusive valuation of the Active Pharmaceutical Ingredient (API) market and it encompasses thoughtful visions, actualities, industry-validated market findings, historic data, and prognoses by means of appropriate set of assumptions and practice. Global Active Pharmaceutical Ingredient (API) market report aids in comprehending market structure and dynamics by recognizing and scrutinizing the market sectors and predicted the global market outlook.

Report Coverage

COVID-19 Impact Assessment on Market Landscape

The report comprises the scrutiny of COVID-19 lock-down impact on the income of market leaders, disrupters and followers. Since lock down was instigated differently in diverse regions and nations, influence of same is also dissimilar across various industry verticals. The research report offers present short-term and long-term influence on the market to assist market participants across value chain makers to formulate the framework for short term and long-lasting tactics for recovery and by region.

Active Pharmaceutical Ingredient (API) market Report empowers readers with all-inclusive market intelligence and offers a granular outline of the market they are operational in. Further this research study delivers exceptional combination of tangible perceptions and qualitative scrutiny to aid companies accomplishes sustainable growth. This report employs industry-leading research practices and tools to assemble all-inclusive market studies, intermingled with pertinent data. Additionally, this report also emphases on the competitive examination of crucial players by analyzing their product portfolio, pricing, gross margins, financial position, growth approaches, and regional occurrence.

North America was the largest regional market for active pharmaceutical ingredients in 2020.

Geographically, the active pharmaceutical ingredients market is segmented into North America, Europe, Asia, and Rest of the World. In 2019, North America accounted for the largest share of the active pharmaceutical ingredients market, followed by Europe and the Asia Pacific. The large share of North America in the global market is attributed to the growing incidence of preventable chronic diseases, increasing government focus on generic drugs, rising demand for biologics and specialty drugs, and technological advancements in the manufacturing processes of APIs

Competitive Rivalry

Foremost players in the market are attentive on adopting corporation strategies to enhance their market share. Some of the prominent tactics undertaken by leading market participants in order to sustain the fierce market completion include collaborations, acquisitions, substantial spending in R&D and the improvement of new-fangled products or reforms among others.

Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.

• Company Overview
• Company Market Share/Positioning Analysis
• Product Offerings
• Financial Performance
• Recent Initiatives
• Key Strategies Adopted by Players
• Vendor Landscape
• List of Suppliers
• List of Buyers

Some of the prominent players in the Active Pharmaceutical Ingredient (API) Market include:  Pfizer Inc., Novartis International AG, Merck & Co., Teva Pharmaceutical Industries Ltd., Mylan N.V., Boehringer Ingelheim, F. Hoffmann-La Roche AG , Sanofi, AbbVie, Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb, and GlaxoSmithKline plc.

Unravelling the Critical Segments

This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects including product type, application/end-user, and region. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for period 2017 to 2027 and covers subsequent region in its scope:

APIs Market, by Type

• Innovative APIs
• Generic APIS

By Type of Manufacturer

• Captive Manufacturers
• Merchant Manufacturers
• Merchant Manufacturers Market, by Type
• Innovative Merchant API Manufacturers
• Generic Merchant API Manufacturers
• Merchant Manufacturers Market, by Type of Synthesis
• Synthetic APIs
• Biotech APIs

By Type of Synthesis

• Synthetic APIs Market
• Synthetic APIs Market, by Type
• Innovative Synthetic APIs
• Generic Synthetic APIs
• Biotech APIs Market
• Biotech APIs Market, by Type
• Innovative Biotech APIs
• Biosimilars
• Biotech APIs Market, by Product
• Monoclonal Antibodies
• Hormones
• Cytokines
• Fusion Proteins
• Therapeutic Enzymes
• Vaccines
• Blood Factors
• Biotech APIs Market, by Expression System
• Mammalian Expression Systems
• Microbial Expression Systems
• Yeast Expression Systems
• Insect Expression Systems
• Other Expression Systems

By Type of Drug

• Prescription Drugs
• Over-the-counter Drugs

By Therapeutic Application

• Communicable Diseases
• Oncology
• Diabetes
• Cardiovascular Disease
• Pain management
• Respiratory Diseases
• Other

By Geography

North America

• U.S.
• Canada

Europe

• Germany
• France
• United Kingdom
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Rest of Latin America

Middle East & Africa (MEA)

• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa

Highlights of the Report:

• Market Penetration: Comprehensive information on the product portfolios of the top players in the market.
• Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market
• Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market
• Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the market

Research Methodology

In the study, a unique research methodology is utilized to conduct extensive research on the growth of the Active Pharmaceutical Ingredient (API) market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the Active Pharmaceutical Ingredient (API) market study are as follows - statistics from government organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, all of whom have contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary and secondary resources acts as a validation from companies in the market, and makes the projections on the growth prospects of the Active Pharmaceutical Ingredient (API) markets more accurate and reliable.

Secondary Research

It involves company databases such as Hoover's: This assists us recognize financial information, structure of the market participants and industry competitive landscape.

The secondary research sources referred in the process are as follows:

• Governmental bodies, and organizations creating economic policies
• National and international social welfare institutions
• Company websites, financial reports and SEC filings, broker and investor reports
• Related patent and regulatory databases
• Statistical databases and market reports
• Corporate Presentations, news, press release, and specification sheet of Manufacturers

Primary Research

Primary research includes face-to face interviews, online surveys, and telephonic interviews.

• Means of primary research: Email interactions, telephonic discussions and Questionnaire based research etc.
• In order to validate our research findings and analysis we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.

Industry participants involved in this research study include:

• CEOs, VPs, market intelligence managers
• Procuring and national sales managers technical personnel, distributors and resellers
• Research analysts and key opinion leaders from various domains

Key Points Covered in Active Pharmaceutical Ingredient (API) market Study:

• Growth of Active Pharmaceutical Ingredient (API) in 2021
• Market Estimates and Forecasts (2017-2027)
•  Brand Share and Market Share Analysis
•  Key Drivers and Restraints Shaping Market Growth
•  Segment-wise, Country-wise, and Region-wise Analysis
•  Competition Mapping and Benchmarking
•  Recommendation on Key Winning Strategies
•  COVID-19 Impact on Demand for Active Pharmaceutical Ingredient (API) and How to Navigate
•  Key Product Innovations and Regulatory Climate
•  Active Pharmaceutical Ingredient (API) Consumption Analysis
•  Active Pharmaceutical Ingredient (API) Production Analysis

• Chapter 1.    Introduction

  1.1.  Research Objective

  1.2.  Scope of the Study

  1.3.  Definition

  Chapter 2.    Research Methodology

  2.1.  Research Approach

  2.2.  Data Sources

  2.3.  Assumptions & Limitations

  Chapter 3.    Executive Summary

  3.1.  Market Snapshot

  Chapter 4.    Market Variables and Scope

  4.1.  Introduction

  4.2.  Market Classification and Scope

  4.3.  Industry Value Chain Analysis

  4.3.1.     Raw Material Procurement Analysis

  4.3.2.     Sales and Distribution Channel Analysis

  4.3.3.     Downstream Buyer Analysis

  Chapter 5.    Market Dynamics Analysis and Trends

  5.1.  Market Dynamics

  5.1.1.     Market Drivers

  5.1.2.     Market Restraints

  5.1.3.     Market Opportunities

  5.2.  Porter’s Five Forces Analysis

  5.2.1.     Bargaining power of suppliers

  5.2.2.     Bargaining power of buyers

  5.2.3.     Threat of substitute

  5.2.4.     Threat of new entrants

  5.2.5.     Degree of competition

  Chapter 6.    Competitive Landscape

  6.1.1.     Company Market Share/Positioning Analysis

  6.1.2.     Key Strategies Adopted by Players

  6.1.3.     Vendor Landscape

  6.1.3.1.          List of Suppliers

  6.1.3.2.          List of Buyers

  Chapter 7.    Global Active Pharmaceutical Ingredient (API) Market, By Type

  7.1.  Active Pharmaceutical Ingredient (API) Market, by Type, 2021-2027

  7.1.1.     Innovative APIs

  7.1.1.1.          Market Revenue and Forecast (2016-2027)

  7.1.2.     Innovative APIs

  7.1.2.1.          Market Revenue and Forecast (2016-2027)

  Chapter 8.    Global Active Pharmaceutical Ingredient (API) Market, By Type of Manufacturer

  8.1.  Active Pharmaceutical Ingredient (API) Market, by Type of Manufacturer, 2021-2027

  8.1.1.     Captive Manufacturers

  8.1.1.1.          Market Revenue and Forecast (2016-2027)

  8.1.2.     Merchant Manufacturers

  8.1.2.1.          Market Revenue and Forecast (2016-2027)

  Chapter 9.    Global Active Pharmaceutical Ingredient (API) Market, By Type of Synthesis

  9.1.  Active Pharmaceutical Ingredient (API) Market, by Type of Synthesis, 2021-2027

  9.1.1.     Synthetic APIs Market

  9.1.1.1.          Market Revenue and Forecast (2016-2027)

  9.1.2.     Biotech APIs Market

  9.1.2.1.          Market Revenue and Forecast (2016-2027)

  Chapter 10.Global Active Pharmaceutical Ingredient (API) Market, By Type of Drug

  10.1.          Active Pharmaceutical Ingredient (API) Market, by Type of Drug, 2021-2027

  10.1.1.  Prescription Drugs

  10.1.1.1.       Market Revenue and Forecast (2016-2027)

  10.1.2.  Over-the-counter Drugs

  10.1.2.1.       Market Revenue and Forecast (2016-2027)

  Chapter 11.Global Active Pharmaceutical Ingredient (API) Market, By Therapeutic Application

  11.1.          Active Pharmaceutical Ingredient (API) Market, by Therapeutic Application, 2021-2027

  11.1.1.  Communicable Diseases

  11.1.1.1.       Market Revenue and Forecast (2016-2027)

  11.1.2.  Oncology

  11.1.2.1.       Market Revenue and Forecast (2016-2027)

  11.1.3.  Diabetes

  11.1.3.1.       Market Revenue and Forecast (2016-2027)

  11.1.4.  Cardiovascular Disease

  11.1.4.1.       Market Revenue and Forecast (2016-2027)

  11.1.5.  Pain management

  11.1.5.1.       Market Revenue and Forecast (2016-2027)

  11.1.6.  Pain management

  11.1.6.1.       Market Revenue and Forecast (2016-2027)

  11.1.7.  Other Therapeutic Applications

  11.1.7.1.       Market Revenue and Forecast (2016-2027)

  Chapter 12.Global Active Pharmaceutical Ingredient (API) Market, Regional Estimates and Trend Forecast

  12.1.          North America

  12.1.1.  Market Revenue and Forecast, by Type (2016-2027)

  12.1.2.  Market Revenue and Forecast, by Type of Manufacturer (2016-2027)

  12.1.3.  Market Revenue and Forecast, by Type of Synthesis (2016-2027)

  12.1.4.  Market Revenue and Forecast, by Type of Drug (2016-2027)

  12.1.5.  Market Revenue and Forecast, by Therapeutic Application (2016-2027)

  12.1.6.  U.S.

  12.1.6.1.       Market Revenue and Forecast, by Type (2016-2027)

  12.1.6.2.       Market Revenue and Forecast, by Type of Manufacturer (2016-2027)

  12.1.6.3.       Market Revenue and Forecast, by Type of Synthesis (2016-2027)

  12.1.6.4.       Market Revenue and Forecast, by Type of Drug (2016-2027)

  12.1.6.5.       Market Revenue and Forecast, by Therapeutic Application (2016-2027)

  12.1.7.  Rest of North America

  12.1.7.1.       Market Revenue and Forecast, by Type (2016-2027)

  12.1.7.2.       Market Revenue and Forecast, by Type of Manufacturer (2016-2027)

  12.1.7.3.       Market Revenue and Forecast, by Type of Synthesis (2016-2027)

  12.1.7.4.       Market Revenue and Forecast, by Type of Drug (2016-2027)

  12.1.7.5.       Market Revenue and Forecast, by Therapeutic Application (2016-2027)

  12.2.          Europe

  12.2.1.  Market Revenue and Forecast, by Type (2016-2027)

  12.2.2.  Market Revenue and Forecast, by Type of Manufacturer (2016-2027)

  12.2.3.  Market Revenue and Forecast, by Type of Synthesis (2016-2027)

  12.2.4.  Market Revenue and Forecast, by Type of Drug (2016-2027)

  12.2.5.  Market Revenue and Forecast, by Therapeutic Application (2016-2027)

  12.2.6.  UK

  12.2.6.1.       Market Revenue and Forecast, by Type (2016-2027)

  12.2.6.2.       Market Revenue and Forecast, by Type of Manufacturer (2016-2027)

  12.2.6.3.       Market Revenue and Forecast, by Type of Synthesis (2016-2027)

  12.2.6.4.       Market Revenue and Forecast, by Type of Drug (2016-2027)

  12.2.6.5.       Market Revenue and Forecast, by Therapeutic Application (2016-2027)

  12.2.7.  Germany

  12.2.7.1.       Market Revenue and Forecast, by Type (2016-2027)

  12.2.7.2.       Market Revenue and Forecast, by Type of Manufacturer (2016-2027)

  12.2.7.3.       Market Revenue and Forecast, by Type of Synthesis (2016-2027)

  12.2.7.4.       Market Revenue and Forecast, by Type of Drug (2016-2027)

  12.2.7.5.       Market Revenue and Forecast, by Therapeutic Application (2016-2027)

  12.2.8.  France

  12.2.8.1.       Market Revenue and Forecast, by Type (2016-2027)

  12.2.8.2.       Market Revenue and Forecast, by Type of Manufacturer (2016-2027)

  12.2.8.3.       Market Revenue and Forecast, by Type of Synthesis (2016-2027)

  12.2.8.4.       Market Revenue and Forecast, by Type of Drug (2016-2027)

  12.2.8.5.       Market Revenue and Forecast, by Therapeutic Application (2016-2027)

  12.2.9.  Rest of Europe

  12.2.9.1.       Market Revenue and Forecast, by Type (2016-2027)

  12.2.9.2.       Market Revenue and Forecast, by Type of Manufacturer (2016-2027)

  12.2.9.3.       Market Revenue and Forecast, by Type of Synthesis (2016-2027)

  12.2.9.4.       Market Revenue and Forecast, by Type of Drug (2016-2027)

  12.2.9.5.       Market Revenue and Forecast, by Therapeutic Application (2016-2027)

  12.3.          APAC

  12.3.1.  Market Revenue and Forecast, by Type (2016-2027)

  12.3.2.  Market Revenue and Forecast, by Type of Manufacturer (2016-2027)

  12.3.3.  Market Revenue and Forecast, by Type of Synthesis (2016-2027)

  12.3.4.  Market Revenue and Forecast, by Type of Drug (2016-2027)

  12.3.5.  Market Revenue and Forecast, by Therapeutic Application (2016-2027)

  12.3.6.  India

  12.3.6.1.       Market Revenue and Forecast, by Type (2016-2027)

  12.3.6.2.       Market Revenue and Forecast, by Type of Manufacturer (2016-2027)

  12.3.6.3.       Market Revenue and Forecast, by Type of Synthesis (2016-2027)

  12.3.6.4.       Market Revenue and Forecast, by Type of Drug (2016-2027)

  12.3.6.5.       Market Revenue and Forecast, by Therapeutic Application (2016-2027)

  12.3.7.  China

  12.3.7.1.       Market Revenue and Forecast, by Type (2016-2027)

  12.3.7.2.       Market Revenue and Forecast, by Type of Manufacturer (2016-2027)

  12.3.7.3.       Market Revenue and Forecast, by Type of Synthesis (2016-2027)

  12.3.7.4.       Market Revenue and Forecast, by Type of Drug (2016-2027)

  12.3.7.5.       Market Revenue and Forecast, by Therapeutic Application (2016-2027)

  12.3.8.  Japan

  12.3.8.1.       Market Revenue and Forecast, by Type (2016-2027)

  12.3.8.2.       Market Revenue and Forecast, by Type of Manufacturer (2016-2027)

  12.3.8.3.       Market Revenue and Forecast, by Type of Synthesis (2016-2027)

  12.3.8.4.       Market Revenue and Forecast, by Type of Drug (2016-2027)

  12.3.8.5.       Market Revenue and Forecast, by Therapeutic Application (2016-2027)

  12.3.9.  Rest of APAC

  12.3.9.1.       Market Revenue and Forecast, by Type (2016-2027)

  12.3.9.2.       Market Revenue and Forecast, by Type of Manufacturer (2016-2027)

  12.3.9.3.       Market Revenue and Forecast, by Type of Synthesis (2016-2027)

  12.3.9.4.       Market Revenue and Forecast, by Type of Drug (2016-2027)

  12.3.9.5.       Market Revenue and Forecast, by Therapeutic Application (2016-2027)

  12.4.          MEA

  12.4.1.  Market Revenue and Forecast, by Type (2016-2027)

  12.4.2.  Market Revenue and Forecast, by Type of Manufacturer (2016-2027)

  12.4.3.  Market Revenue and Forecast, by Type of Synthesis (2016-2027)

  12.4.4.  Market Revenue and Forecast, by Type of Drug (2016-2027)

  12.4.5.  Market Revenue and Forecast, by Therapeutic Application (2016-2027)

  12.4.6.  GCC

  12.4.6.1.       Market Revenue and Forecast, by Type (2016-2027)

  12.4.6.2.       Market Revenue and Forecast, by Type of Manufacturer (2016-2027)

  12.4.6.3.       Market Revenue and Forecast, by Type of Synthesis (2016-2027)

  12.4.6.4.       Market Revenue and Forecast, by Type of Drug (2016-2027)

  12.4.6.5.       Market Revenue and Forecast, by Therapeutic Application (2016-2027)

  12.4.7.  North Africa

  12.4.7.1.       Market Revenue and Forecast, by Type (2016-2027)

  12.4.7.2.       Market Revenue and Forecast, by Type of Manufacturer (2016-2027)

  12.4.7.3.       Market Revenue and Forecast, by Type of Synthesis (2016-2027)

  12.4.7.4.       Market Revenue and Forecast, by Type of Drug (2016-2027)

  12.4.7.5.       Market Revenue and Forecast, by Therapeutic Application (2016-2027)

  12.4.8.  South Africa

  12.4.8.1.       Market Revenue and Forecast, by Type (2016-2027)

  12.4.8.2.       Market Revenue and Forecast, by Type of Manufacturer (2016-2027)

  12.4.8.3.       Market Revenue and Forecast, by Type of Synthesis (2016-2027)

  12.4.8.4.       Market Revenue and Forecast, by Type of Drug (2016-2027)

  12.4.8.5.       Market Revenue and Forecast, by Therapeutic Application (2016-2027)

  12.4.9.  Rest of MEA

  12.4.9.1.       Market Revenue and Forecast, by Type (2016-2027)

  12.4.9.2.       Market Revenue and Forecast, by Type of Manufacturer (2016-2027)

  12.4.9.3.       Market Revenue and Forecast, by Type of Synthesis (2016-2027)

  12.4.9.4.       Market Revenue and Forecast, by Type of Drug (2016-2027)

  12.4.9.5.       Market Revenue and Forecast, by Therapeutic Application (2016-2027)

  12.5.          Latin America

  12.5.1.  Market Revenue and Forecast, by Type (2016-2027)

  12.5.2.  Market Revenue and Forecast, by Type of Manufacturer (2016-2027)

  12.5.3.  Market Revenue and Forecast, by Type of Synthesis (2016-2027)

  12.5.4.  Market Revenue and Forecast, by Type of Drug (2016-2027)

  12.5.5.  Market Revenue and Forecast, by Therapeutic Application (2016-2027)

  12.5.6.  Brazil

  12.5.6.1.       Market Revenue and Forecast, by Type (2016-2027)

  12.5.6.2.       Market Revenue and Forecast, by Type of Manufacturer (2016-2027)

  12.5.6.3.       Market Revenue and Forecast, by Type of Synthesis (2016-2027)

  12.5.6.4.       Market Revenue and Forecast, by Type of Drug (2016-2027)

  12.5.6.5.       Market Revenue and Forecast, by Therapeutic Application (2016-2027)

  12.5.7.  Rest of LATAM

  12.5.7.1.       Market Revenue and Forecast, by Type (2016-2027)

  12.5.7.2.       Market Revenue and Forecast, by Type of Manufacturer (2016-2027)

  12.5.7.3.       Market Revenue and Forecast, by Type of Synthesis (2016-2027)

  12.5.7.4.       Market Revenue and Forecast, by Type of Drug (2016-2027)

  12.5.7.5.       Market Revenue and Forecast, by Therapeutic Application (2016-2027)

  Chapter 13.   Company Profiles

  13.1.                 Pfizer Inc.

  13.1.1.  Company Overview

  13.1.2.  Product Offerings

  13.1.3.  Financial Performance

  13.1.4.  Recent Initiatives

  13.2.                 Novartis International AG

  13.2.1.  Company Overview

  13.2.2.  Product Offerings

  13.2.3.  Financial Performance

  13.2.4.  Recent Initiatives

  13.3.                 Merck & Co.

  13.3.1.  Company Overview

  13.3.2.  Product Offerings

  13.3.3.  Financial Performance

  13.3.4.  Recent Initiatives

  13.4.                 Teva Pharmaceutical Industries Ltd.

  13.4.1.  Company Overview

  13.4.2.  Product Offerings

  13.4.3.  Financial Performance

  13.4.4.  Recent Initiatives

  13.5.                 Mylan N.V.

  13.5.1.  Company Overview

  13.5.2.  Product Offerings

  13.5.3.  Financial Performance

  13.5.4.  Recent Initiatives

  13.6.                 Boehringer Ingelheim

  13.6.1.  Company Overview

  13.6.2.  Product Offerings

  13.6.3.  Financial Performance

  13.6.4.  Recent Initiatives

  13.7.                 F. Hoffmann-La Roche AG

  13.7.1.  Company Overview

  13.7.2.  Product Offerings

  13.7.3.  Financial Performance

  13.7.4.  Recent Initiatives

  13.8.                 Sanofi

  13.8.1.  Company Overview

  13.8.2.  Product Offerings

  13.8.3.  Financial Performance

  13.8.4.  Recent Initiatives

  13.9.                 AbbVie

  13.9.1.  Company Overview

  13.9.2.  Product Offerings

  13.9.3.  Financial Performance

  13.9.4.  Recent Initiatives

  13.10.              Eli Lilly and Company

  13.10.1.                   Company Overview

  13.10.2.                   Product Offerings

  13.10.3.                   Financial Performance

  13.10.4.                   Recent Initiatives

  Chapter 14.   Research Methodology

  14.1.                 Primary Research

  14.2.                 Secondary Research

  14.3.                 Assumptions

  Chapter 15.   Appendix

  15.1.                 About Us

  15.2.                 Glossary of Terms